Clinical predictors and time course of the improvement in β-cell function with short-term intensive insulin therapy in patients with Type 2 diabetes

Diabetic Medicine

Volumn 32, Issue 5, 2015, Pages 645-652

  Stein, C M ^a   Kramer, C K ^a,b   Zinman, B ^a,b,c   Choi, H ^a   Opsteen, C ^a   Retnakaran, R ^a,b,c  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c MOUNT SINAI HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN; INSULIN ASPART; INSULIN DETEMIR; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN;

ADULT; ARTICLE; CELL FUNCTION; CONTROLLED STUDY; DIABETIC PATIENT; DISEASE DURATION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; INTENSIVE CARE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PREDICTOR VARIABLE; SHORT COURSE THERAPY; TIME; TREATMENT RESPONSE; AGED; BLOOD; COMPARATIVE STUDY; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; GLUCOSE TOLERANCE TEST; INCIDENCE; METABOLISM; MIDDLE AGED; PHYSIOLOGY; PREDICTIVE VALUE; QUESTIONNAIRE; STATISTICAL MODEL; TIME FACTOR; TREATMENT OUTCOME;

AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCOSE TOLERANCE TEST; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INCIDENCE; INSULIN; INSULIN-SECRETING CELLS; LOGISTIC MODELS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; SURVEYS AND QUESTIONNAIRES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84928081134     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/dme.12671     Document Type: Article

References (19)

1. Kahn SE, Zraika S, Utzschneider KM, Hull RL. The β-cell lesion in type 2 diabetes: there has to be a primary functional abnormality. Diabetologia 2009; 52: 1003-1012.
2. Wajchenberg BL. Beta-cell failure in diabetes and preservation by clinical treatment. Endocrin Rev 2007; 28: 187-218.
3. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35: 1364-1379.
4. Turner RC, Cull CA, Frighi V, Hollman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA 1999; 281: 2005-2012.
5. Retnakaran R, Zinman B. Short-term intensified insulin treatment in type 2 diabetes: long-term effects on β-cell function. Diabetes Obes Metab 2012; 14: 161-166.
6. Weng J, Li Y, Xu W, Shi L, Zhang Q, Zhu D et al. Effect of intensive insulin therapy on ß-cell function and glycemic control in patients with newly diagnosed type 2 diabetes: a multicenter randomised parallel-group trial. Lancet 2008; 371: 1753-1760.
7. Ryan EA, Imes S, Wallace C. Short-term intensive insulin therapy in newly diagnosed type 2 diabetes. Diabetes Care 2004; 27: 1028-1032.
8. Li Y, Xu W, Liao Z, Yao B, Chen X, Huang Z et al. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of ß-cell function. Diabetes Care 2004; 27: 2597-2602.
9. Chen HS, Wu TE, Jap TS, Hsiao LC, Lee SH, Lin HD. Beneficial effects of insulin on glycemic control and β-cell function in newly diagnosed type 2 diabetes with severe hyperglycemia after short-term intensive insulin therapy. Diabetes Care 2008; 31: 1927-1932.
10. Chen A, Huang Z, Wan X, Deng W, Wu J, Li L et al. Attitudes toward diabetes affect maintenance of drug-free remission in patients with newly diagnosed type 2 diabetes after short-term continuous subcutaneous insulin infusion treatment. Diabetes Care 2012; 35: 474-481.
11. Park S, Choi SB. Induction of long-term normoglycemia without medication in Korean type 2 diabetes patients after continuous subcutaneous insulin infusion therapy. Diabetes Metab Res Rev 2003; 19: 124-130.
12. Kramer C, Zinman B, Retnakaran R. Short-term intensive insulin therapy and its impact on type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 2013; 1: 28-34.
13. Retnakaran R, Yakubovich N, Qi Y, Opsteen C, Zinman B. The response to short-term intensive insulin therapy in type 2 diabetes. Diabetes Obes Metab 2010; 12: 65-71.
14. Retnakaran R, Qi Y, Opsteen C, Vivero E, Zinman B. Initial short-term intensive insulin therapy as a strategy for evaluating the preservation of β-cell function with oral antidiabetic medications: a pilot study with sitagliptin. Diabetes Obes Metab 2010; 12: 909-915.
15. Kramer CK, Choi H, Zinman B, Retnakaran R. Determinants of reversibility of β-cell dysfunction in response to short-term intensive insulin therapy in patients with early type 2 diabetes. Am J Physiol Endocrinol Metab 2013; 305: E1398-E1407.
16. Robertson RP, Harmon J, Tran PO, Tanaka Y, Takahashi H. Glucose toxicity in cells: type 2 diabetes, good radicals gone bad, and the glutathione connection. Diabetes 2003; 52: 581-587.
17. Kramer CK, Choi H, Zinman B, Retnakaran R. Glycemic variability in patients with early type 2 diabetes: the impact of improvement in beta-cell function. Diabetes Care 2014; 37: 1116-1123.
18. Kramer CK, Vuksan V, Choi H, Zinman B, Retnakaran R. Emerging parameters of the insulin and glucose response on the oral glucose tolerance test: reproducibility and implications for glucose homeostasis in individuals with and without diabetes. Diabetes Res Clin Pract 2014; 105: 88-95.
19. DeVries JH. Intensive insulin therapy for type 2 diabetes at diagnosis. Lancet Diabetes Endocrinol 2013; 1: 3-4.